BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
“Diversified nanoparticles”deliver mRNA to enhance tumor immunotherapy
meng zhang (Air Force Medical University.), yuexia zhong1,# (the Fourth Military Medical University), yuan gao (The Fourth Military Medical University), dong fan4 (Air Force Medical University), xiyan lu1 (the Fourth Military Medical University), wei he 2,* (The Fourth Military Medical University)
1Outpatient Department of the Second Affiliated Hospital and 2State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, the Fourth Military Medical University,
3Department of Pharmacology, School of Pharmacy and 4Department of General Surgery, Tangdu Hospital, Air Force Medical University
Abstract
Solid tumor therapies often have suboptimal outcomes due to limited efficacy and severe side effects. In contrast, tumor immunotherapy shows promise with reduced side effects and potential long-term benefits. However, challenges such as variable patient responses and immune-related adverse events hinder its widespread application. Recent advancements in mRNA technology have revolutionized cancer immunotherapy. mRNA’s versatility as a vaccine and therapeutic agent addresses the limitations of traditional approaches by reducing in vivo toxicity and enhancing immune response activation. The synergy between mRNA technology and immunotherapy is being increasingly utilized to improve cancer treatment efficacy. One critical aspect of maximizing the therapeutic impact of mRNA-based treatments is selecting an effective delivery system. Nanoparticles have emerged as a transformative solution due to their size properties and material characteristics, enabling targeted and efficient delivery of mRNA to tumor tissues or immune cells. This precision delivery mechanism significantly enhances the effectiveness of immunotherapy, representing a significant advancement in cancer treatment. This review aims to explore how mRNA delivery via nanoparticles enhances tumor immunotherapy. By examining its applications and challenges, we provide insights and strategic perspectives for advancing this innovative therapeutic approach.
Abstract, Accepted Manuscript [Submitted on October 21, 2024, Accepted on January 15, 2025]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd